This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Enzalutamide for treating hormone-sensitive metastatic prostate cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Enzalutamide plus androgen deprivation therapy (ADT) is recommended, within its marketing authorisation, as an option for treating hormone-sensitive metastatic prostate cancer in adults


  • enzalutamide (formerly known as MDV3100) is a targeted androgen-receptor inhibitor that competitively binds to the ligand-binding domain of the androgen receptor and inhibits androgen-receptor translocation to the cell nucleus, recruitment of androgen-receptor cofactors, and androgen-receptor binding to DNA
    • enzalutamide significantly decreased the risk of radiographic progression and death and delayed the initiation of chemotherapy in men with metastatic prostate cancer (2)


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.


Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.